elder law weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of elder law weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pfizer Inc.
Chemotherapy including epirubicin may improve survival for some patients
June 23rd, 2004
New data presented at the 2004 meeting of the American Society of Clinical Oncology suggest that a chemotherapy regimen including epirubicin (Pfizer brand name: Ellence) may significantly improve survival in breast cancer patients at highest risk of recurrence. Results from the German AGO multi-center Phase III trial show that a sequential dose-dense chemotherapy regimen of Ellence, paclitaxel, and cyclophosphamide (ETC) as adjuvant therapy in high-risk breast cancer patients significantly improves disease-free survival (DFS) and overall survival (OS). Interim results of a study with over 1,200 patients having four or more positive nodes, comparing...
Source: elder law weekly (2004-06-23)
|
